BindingDB logo
myBDB logout

20 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review
PMIDDataArticle TitleOrganization
27889630 6 1,2,3-Triazolyl ester of Ketorolac: A"Click Chemistry"-based highly potent PAK1-blocking cancer-killer.EBI Kagoshima University
23103095 125 Hit to Lead optimization of a novel class of squarate-containing polo-like kinases inhibitors.EBI Abbott Laboratories
20471253 32 Substituted 2H-isoquinolin-1-ones as potent Rho-kinase inhibitors: part 3, aryl substituted pyrrolidines.EBI Boehringer Ingelheim Pharmaceuticals Inc
20000469 179 Hit to lead account of the discovery of bisbenzamide and related ureidobenzamide inhibitors of Rho kinase.EBI Boehringer Ingelheim Pharmaceuticals Inc
16408091 2 Secramine inhibits Cdc42-dependent functions in cells and Cdc42 activation in vitro.EBI Harvard Medical School
20462760 70 Substituted 2H-isoquinolin-1-one as potent Rho-Kinase inhibitors. Part 1: Hit-to-lead account.EBI Boehringer Ingelheim Pharmaceuticals Inc
19716293 22 Structure-activity relationship of isoform selective inhibitors of Rac1/1b GTPase nucleotide binding.EBI Exonhit Therapeutics, SA
23952265 84 Testing the substrate-envelope hypothesis with designed pairs of compounds.BDB Massachusetts Institute of Technology
23899657 3 Binding of (5S)-penicilloic acid to penicillin binding protein 3.BDB University of Oxford
24171552 52 Expanding the Scope of Human DNA Polymerase and Inhibitors.BDB University of Konstanz
24070067 20 Fluorescence Linked Enzyme Chemoproteomic Strategy for Discovery of a Potent and Selective DAPK1 and ZIPK Inhibitor.BDB Duke University Medical Center
24004176 16 Selectively targeting prostate cancer with antiandrogen equipped histone deacetylase inhibitors.BDB Georgia Institute of Technology